JP2009149648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009149648A5 JP2009149648A5 JP2008325914A JP2008325914A JP2009149648A5 JP 2009149648 A5 JP2009149648 A5 JP 2009149648A5 JP 2008325914 A JP2008325914 A JP 2008325914A JP 2008325914 A JP2008325914 A JP 2008325914A JP 2009149648 A5 JP2009149648 A5 JP 2009149648A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aminomethyl
- carbonyl
- isobutanoyloxyethoxy
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000013078 crystal Substances 0.000 claims 17
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 claims 17
- 238000010521 absorption reaction Methods 0.000 claims 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- -1 α-isobutanoyloxyethoxy Chemical group 0.000 claims 1
- 150000003953 γ-lactams Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51128703P | 2003-10-14 | 2003-10-14 | |
| US60/511,287 | 2003-10-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Division JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009149648A JP2009149648A (ja) | 2009-07-09 |
| JP2009149648A5 true JP2009149648A5 (enExample) | 2009-11-12 |
| JP4913796B2 JP4913796B2 (ja) | 2012-04-11 |
Family
ID=34465215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Expired - Lifetime JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
| JP2008325914A Expired - Lifetime JP4913796B2 (ja) | 2003-10-14 | 2008-12-22 | γ−アミノ酪酸アナログの結晶形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Expired - Lifetime JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
Country Status (22)
| Country | Link |
|---|---|
| US (10) | US8026279B2 (enExample) |
| EP (1) | EP1677767B1 (enExample) |
| JP (2) | JP4308263B2 (enExample) |
| KR (1) | KR101096480B1 (enExample) |
| CN (1) | CN1867322B (enExample) |
| AT (1) | ATE516801T1 (enExample) |
| AU (1) | AU2004282192B2 (enExample) |
| BR (1) | BRPI0415288B8 (enExample) |
| CA (1) | CA2541752C (enExample) |
| DK (1) | DK1677767T3 (enExample) |
| ES (1) | ES2368916T3 (enExample) |
| IL (2) | IL174600A (enExample) |
| MX (1) | MXPA06004088A (enExample) |
| NO (1) | NO338275B1 (enExample) |
| NZ (1) | NZ546381A (enExample) |
| PL (1) | PL1677767T3 (enExample) |
| PT (1) | PT1677767E (enExample) |
| RU (1) | RU2412162C2 (enExample) |
| SG (1) | SG147437A1 (enExample) |
| SI (1) | SI1677767T1 (enExample) |
| WO (1) | WO2005037784A2 (enExample) |
| ZA (1) | ZA200602722B (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| JP2007505149A (ja) * | 2003-09-11 | 2007-03-08 | ゼノポート，インコーポレイティド | ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防 |
| WO2005027850A2 (en) * | 2003-09-17 | 2005-03-31 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| SI1677767T1 (sl) * | 2003-10-14 | 2011-11-30 | Xenoport Inc | Kristalinična oblika analoga gama-aminomaslene kisline |
| US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| CN101068538A (zh) | 2004-11-04 | 2007-11-07 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
| KR20080022203A (ko) * | 2005-06-20 | 2008-03-10 | 제노포트 인코포레이티드 | 트라넥삼산의 아실옥시알킬 카르바메이트 프로드러그, 합성방법 및 용도 |
| CA2672044A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| TWI369982B (en) * | 2007-01-11 | 2012-08-11 | Xenoport Inc | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| WO2009061934A1 (en) * | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
| US20090318728A1 (en) * | 2008-06-24 | 2009-12-24 | Teva Pharmaceutical Industries Ltd. | Processes for preparing prodrugs of gabapentin and intermediates thereof |
| WO2010003046A2 (en) * | 2008-07-02 | 2010-01-07 | Teva Pharmaceutical Industries Ltd. | Gabapentin enacarbil salts and processes for their preparation |
| US7989641B2 (en) | 2008-08-07 | 2011-08-02 | Xenoport, Inc. | Methods of synthesizing N-hydroxysuccinimidyl carbonates |
| WO2010017504A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| US8283487B2 (en) | 2008-11-26 | 2012-10-09 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation and purification of gabapentin enacarbil |
| US20100160666A1 (en) * | 2008-12-23 | 2010-06-24 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin enacarbil intermediate |
| US20110303570A1 (en) * | 2009-03-02 | 2011-12-15 | Astellas Pharma Inc. | Package of solid pharmaceutical preparation |
| NZ594648A (en) * | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
| US20100226981A1 (en) * | 2009-03-06 | 2010-09-09 | Xenoport, Inc. | Oral dosage forms having a high loading of a gabapentin prodrug |
| WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
| WO2011091164A1 (en) | 2010-01-22 | 2011-07-28 | Xenoport, Inc. | Oral dosage forms having a high loading of a tranexamic acid prodrug |
| US20110263701A1 (en) * | 2010-04-21 | 2011-10-27 | Sigal Blau | Gabapentin enacarbil compositions |
| WO2013008182A1 (en) * | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
| WO2013168019A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neuropathic pain |
| AU2013257706A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
| JP2015522531A (ja) | 2012-05-07 | 2015-08-06 | セリックスビオ プライヴェート リミテッド | 神経筋疾患及び神経変性疾患の治療のための組成物及び方法 |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
| SG11201407319YA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013175359A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| EP2892878A4 (en) | 2012-09-08 | 2016-02-24 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER |
| WO2014134005A2 (en) | 2013-02-26 | 2014-09-04 | Xenoport, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP3004049B1 (en) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| WO2016110865A1 (en) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
| CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
| JP6564868B2 (ja) | 2014-10-27 | 2019-08-21 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩 |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| RU2739192C1 (ru) * | 2020-06-18 | 2020-12-21 | федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Способ лечения абстинентного синдрома, с целью превенции развития психоза, у лиц с зависимостью от синтетических агонистов рецепторов гамма-аминомасляной кислоты: бутиролактона, 1,4-бутандиола |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| JPS62258337A (ja) | 1986-04-30 | 1987-11-10 | Kuraray Co Ltd | ４−ヒドロキシ−２，４，６−トリメチル−２，５−シクロヘキサジエン−１−オンの精製法 |
| DE3815221C2 (de) * | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| DE3928183A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| US5084169A (en) * | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| PT641330E (pt) | 1992-05-20 | 2002-03-28 | Univ Northwestern | Analogos de gaba e de acido l-glutamico para o tratamento de doencas do sistema nervoso central |
| DK0888325T3 (da) | 1996-02-07 | 2002-09-16 | Warner Lambert Co | Cykliske aminosyrer som farmaceutiske midler |
| EA002765B1 (ru) | 1996-03-14 | 2002-08-29 | Варнер-Ламберт Компани | Производные циклической аминокислоты, фармацевтическая композиция на их основе и способ лечения эпилепсии, приступов слабости, гипокинезии, черепных нарушений, нейродегенеративных или невропатологических нарушений, депрессий, состояний тревоги и паники и боли |
| DE69709070T2 (de) | 1996-03-14 | 2002-06-20 | Warner-Lambert Co., Morris Plains | Verbrückte zyklische aminosäuren als pharmazeutische mittel |
| KR100491282B1 (ko) * | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| CA2263663C (en) | 1996-10-23 | 2006-05-30 | Justin Stephen Bryans | Substituted gamma aminobutyric acids as pharmaceutical agents |
| AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
| DE69834204T2 (de) | 1997-10-27 | 2007-03-29 | Warner-Lambert Co. Llc | Zyklische aminosäuren und deren derivate als arzneimittel |
| PL341231A1 (en) | 1997-12-16 | 2001-03-26 | Warner Lambert Co | 4(3)-substitute derivatives of 4(3)aminomethyl(thio)pyrane or piperidine derivatives (analogues of garbapentin), their production and application in treating neurological disorders |
| ES2227896T3 (es) | 1997-12-16 | 2005-04-01 | Warner-Lambert Company Llc | Derivados de 1-aminometil-cicloalcanos sustituidos en 1 (=analogos de gabapentina), su preparacion y su uso en el tratamiento de trastornos neurologicos. |
| NZ503981A (en) | 1997-12-16 | 2002-12-20 | Warner Lambert Co | Novel amines, pharmaceutical compositions containing these amines, and uses thereof |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| WO1999037296A1 (en) | 1998-01-23 | 1999-07-29 | Warner-Lambert Company | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
| WO1999061424A1 (en) | 1998-05-26 | 1999-12-02 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| AUPP396998A0 (en) | 1998-06-09 | 1998-07-02 | University Of Melbourne, The | A method for increasing the permeability of wood |
| PT1121114E (pt) | 1998-10-16 | 2007-03-30 | Warner Lambert Co | Utilização de análogos gaba para a produção de um medicamento para o tratamento da mania e da doença bipolar |
| WO2000031020A1 (en) | 1998-11-25 | 2000-06-02 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
| EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| ES2313880T3 (es) | 1999-04-08 | 2009-03-16 | Warner-Lambert Company Llc | Procedimiento para el tratamiento de la icontinencia. |
| CA2378918C (en) * | 1999-07-22 | 2007-01-23 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
| GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| EP1296671B1 (en) | 2000-06-26 | 2008-03-26 | Warner-Lambert Company LLC | Gabapentin analogues for sleep disorders |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| WO2002028881A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| AU2002243204A1 (en) | 2000-10-06 | 2002-06-11 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| WO2002032376A2 (en) | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| WO2002042414A2 (en) | 2000-11-17 | 2002-05-30 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| JP2002346303A (ja) | 2001-05-28 | 2002-12-03 | Mitsubishi Chemicals Corp | 晶析方法 |
| JP2002355501A (ja) | 2001-05-30 | 2002-12-10 | Sumitomo Chem Co Ltd | 滴下晶析方法 |
| US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ATE540678T1 (de) | 2001-06-11 | 2012-01-15 | Xenoport Inc | Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| AU2002316231A1 (en) * | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| JP2006522146A (ja) * | 2003-03-31 | 2006-09-28 | ゼノポート，インコーポレイティド | Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防 |
| US6816787B2 (en) | 2003-03-31 | 2004-11-09 | Schlumberger Technology Corporation | Generating and displaying a virtual core and a virtual plug associated with a selected piece of the virtual core |
| US7662987B2 (en) * | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
| JP2007505149A (ja) * | 2003-09-11 | 2007-03-08 | ゼノポート，インコーポレイティド | ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防 |
| WO2005027850A2 (en) * | 2003-09-17 | 2005-03-31 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| SI1677767T1 (sl) * | 2003-10-14 | 2011-11-30 | Xenoport Inc | Kristalinična oblika analoga gama-aminomaslene kisline |
| EP1716115B1 (en) * | 2003-12-30 | 2013-02-27 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| CN101068538A (zh) * | 2004-11-04 | 2007-11-07 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
| CA2669246A1 (en) * | 2006-11-14 | 2008-05-22 | Xenoport, Inc. | Use of gabapentin and pregabalin prodrugs for treating tinnitus |
| CA2672044A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
-
2004
- 2004-10-14 SI SI200431753T patent/SI1677767T1/sl unknown
- 2004-10-14 PL PL04795177T patent/PL1677767T3/pl unknown
- 2004-10-14 PT PT04795177T patent/PT1677767E/pt unknown
- 2004-10-14 MX MXPA06004088A patent/MXPA06004088A/es active IP Right Grant
- 2004-10-14 RU RU2006116470/04A patent/RU2412162C2/ru not_active IP Right Cessation
- 2004-10-14 SG SG200807649-9A patent/SG147437A1/en unknown
- 2004-10-14 JP JP2006535673A patent/JP4308263B2/ja not_active Expired - Lifetime
- 2004-10-14 AU AU2004282192A patent/AU2004282192B2/en not_active Ceased
- 2004-10-14 CN CN200480030148.4A patent/CN1867322B/zh not_active Expired - Fee Related
- 2004-10-14 KR KR1020067007286A patent/KR101096480B1/ko not_active Expired - Lifetime
- 2004-10-14 DK DK04795177.7T patent/DK1677767T3/da active
- 2004-10-14 ES ES04795177T patent/ES2368916T3/es not_active Expired - Lifetime
- 2004-10-14 AT AT04795177T patent/ATE516801T1/de active
- 2004-10-14 BR BRPI0415288A patent/BRPI0415288B8/pt not_active IP Right Cessation
- 2004-10-14 US US10/966,507 patent/US8026279B2/en active Active
- 2004-10-14 NZ NZ546381A patent/NZ546381A/en not_active IP Right Cessation
- 2004-10-14 WO PCT/US2004/033979 patent/WO2005037784A2/en not_active Ceased
- 2004-10-14 EP EP04795177A patent/EP1677767B1/en not_active Expired - Lifetime
- 2004-10-14 CA CA2541752A patent/CA2541752C/en not_active Expired - Lifetime
-
2006
- 2006-03-27 IL IL174600A patent/IL174600A/en active IP Right Grant
- 2006-04-03 ZA ZA2006/02722A patent/ZA200602722B/en unknown
- 2006-05-11 NO NO20062112A patent/NO338275B1/no not_active IP Right Cessation
-
2008
- 2008-12-22 JP JP2008325914A patent/JP4913796B2/ja not_active Expired - Lifetime
-
2009
- 2009-08-26 US US12/548,200 patent/US20100056632A1/en not_active Abandoned
- 2009-12-08 IL IL202603A patent/IL202603A/en active IP Right Grant
-
2010
- 2010-10-04 US US12/897,567 patent/US20110021628A1/en not_active Abandoned
-
2011
- 2011-06-20 US US13/164,620 patent/US8686034B2/en not_active Expired - Lifetime
-
2014
- 2014-03-12 US US14/206,893 patent/US9150503B2/en not_active Expired - Lifetime
-
2015
- 2015-08-20 US US14/831,688 patent/US20150353483A1/en not_active Abandoned
-
2017
- 2017-03-13 US US15/457,191 patent/US20170183296A1/en not_active Abandoned
-
2019
- 2019-01-29 US US16/261,191 patent/US20190152900A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,113 patent/US20200283376A1/en not_active Abandoned
-
2021
- 2021-09-20 US US17/479,382 patent/US20220251031A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009149648A5 (enExample) | ||
| ES2415107T3 (es) | (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, nuevas formas de sales, y métodos de usos de los mismos | |
| JP2010514806A5 (enExample) | ||
| AU2017209250B2 (en) | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite, and preparation method thereof | |
| JP2010514807A5 (enExample) | ||
| US20240165097A1 (en) | Pharmaceutical composition for the treatment of alzheimer's disease or dementia | |
| ES2503465T3 (es) | Preparación y aplicaciones terapéuticas de (2S,3R)-N-2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-di-fluorobenzamida | |
| JP2011522827A5 (enExample) | ||
| JP2011516417A5 (enExample) | ||
| TW201204724A (en) | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives | |
| JP2012082215A5 (enExample) | ||
| ME02747B (me) | Kristalni oblik gama ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| TW200808726A (en) | Novel polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine | |
| CN103113405B (zh) | 苯磷硫胺多晶型体、制备方法及其应用 | |
| CN102351857A (zh) | 盐酸托烷司琼化合物 | |
| JP2022511869A (ja) | ムスカリンｍ１および／またはｍ４受容体アゴニストとしての二環式アザ化合物 | |
| JP2025521564A (ja) | Ｒ－ｍｄｍａ結晶形態 | |
| JP2012533559A5 (enExample) | ||
| JP2024009114A (ja) | ミネラルコルチコイド受容体拮抗剤としての化合物の結晶形及びその調製方法 | |
| TW200845977A (en) | Sub-type selective azabicycloalkane derivatives | |
| JP2010540470A5 (enExample) | ||
| JP2012512145A (ja) | フリバンセリンの結晶性の塩形態 | |
| JP2009541455A5 (enExample) | ||
| CA2881182C (en) | Piperidinium quaternary salts | |
| JP2019517536A5 (enExample) |